TOKYO - Chugai Pharmaceutical Co., Ltd. (Head office: Tokyo; President & CEO: Osamu Okuda; 'Chugai') and SBI Pharmaceuticals Co., Ltd. (Head office: Tokyo; Representative Director & President: Yoshitaka Kitao; 'SBI Pharma') announced that the companies decided to terminate the license agreement for the photodynamic diagnostic agent 'ALAGLIO Divided Granules 1.5g ('ALAGLIO')' and that Chugai will consequently discontinue marketing of the product.
Both companies entered into a license agreement for ALAGLIO on March 13, 2017 which granted Chugai exclusive marketing rights of ALAGLIO in Japan. SBI Pharma obtained regulatory approval for ALAGLIO on September 27, 2017 for the indication of diagnostic agent to visualize non-muscle invasive bladder cancer at the operation of its transurethral resection, and Chugai launched the product on December 19 after the product had been listed on the National Health Insurance reimbursement price list on November 22.
Chugai will discontinue marketing and information provision for ALAGLIO on May 31, 2021. SBI Pharma will announce how these activities will be conducted from June 1, 2021.
Chugai and SBI Pharma will corporate to accomplish a smooth transition and maintain promotion of proper use of the product during the transition period.
Trademarks used or mentioned in this release are protected by law.
Corporate Communications Dept.
Chugai Pharmaceutical Co., Ltd.
Media Relations Group
Investor Relations Group
SBI Pharmaceuticals Co., Ltd.
Marketing & Sales Dept.
(C) 2021 Electronic News Publishing, source ENP Newswire